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Abstract
Background: The molecular mechanisms responsible for the survival and preservation of function for adult
parasympathetic ganglion neurons following injury remain incompletely understood. However, advances in the
neurobiology of growth factors, neural development, and prevention of cell death have led to a surge of clinical
interest for protective and regenerative neuromodulatory strategies, as surgical therapies for prostate, bladder,
and colorectal cancers often result in neuronal axotomy and debilitating loss of sexual function or continence. In
vitro studies have identified neurturin, a glial cell line-derived neurotrophic factor, as a neuromodulator for pelvic
cholinergic neurons. We present the first in vivo report of the effects of neurturin upon the recovery of erectile
function following bilateral cavernous nerve crush injury in the rat.
Methods: In these experiments, groups (n = 8 each) consisted of uninjured controls and animals treated with
injection of albumin (blinded crush control group), extended release neurotrophin-4 or neurturin to the site of
cavernous nerve crush injury (100 μg per animal). After 5 weeks, recovery of erectile function (treatment effect)
was assessed by cavernous nerve electrostimulation and peak aortic pressures were measured. Investigators were
unblinded to specific treatments after statistical analyses were completed.
Results: Erectile dysfunction was not observed in the sham group (mean maximal intracavernous pressure [ICP]
increase of 117.5 ± 7.3 cmH2O), whereas nerve injury and albumin treatment (control) produced a significant
reduction in ICP elevation of 40.0 ± 6.3 cmH2O. Neurturin facilitated the preservation of erectile function, with
an ICP increase of 55% at 62.0 ± 9.2 cmH2O (p < 0.05 vs control). Extended release neurotrophin-4 did not
significantly enhance recovery of erectile function with an ICP change of 46.9 ± 9.6. Peak aortic blood pressures
did not differ between groups. No significant pre- and post-treatment weight differences were observed between
control, neurotrophin-4 and neurturin cohorts. All animals tolerated the five-week treatment course.
Conclusion: Treatment with neurturin at the site of cavernous nerve crush injury facilitates recovery of erectile
function. Results support further investigation of neurturin as a neuroprotective and/or neuroregenerative agent
facilitating functional recovery after cavernous or other pelvic autonomic nerve injuries.
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Background
Urinary incontinence and erectile dysfunction remain a
common cause of debilitating post-operative morbidity
for a significant proportion of patients undergoing radical
therapies for prostate, bladder, and colorectal cancers, as
pelvic autonomic neurons are inadvertently axotomized,
lacerated, or stretched at time of surgery [1]. For example,
contemporary series report that the probability of erectile
dysfunction following radical prostatectomy for clinically
localized cancer of the prostate is 30–80% at 24 months.
Despite advances in surgical technique, most men dem-
onstrate compromised erectile function (incomplete,
delayed, or lack of post-surgical potency) as varying
degrees of cavernous nerve damage occur even with bilat-
eral nerve-sparing procedures [2].
The emerging concept of neuromodulatory therapy recog-
nizes that although the peripheral nervous system demon-
strates an intrinsic ability to regenerate after injury, this
innate response is somewhat limited and does not usually
allow for a full recovery of function [3]. Accumulating evi-
dence suggests that a return to potency following injury to
the cavernous nerves is partially dependent upon axonal
regeneration in the remaining neural tissues and several
treatment strategies offering the potential to facilitate
recovery are currently under investigation in animal mod-
els, including neurotrophins, immunophilin ligands,
phosphodiesterase-5 inhibitors, and embryonic stem cells
[1,4-6]. Collateral sprouting of axons occurs acutely fol-
lowing injury to adult peripheral neurons and growth
cones target local environments supportive of regenera-
tion. Molecular mechanisms of this process remain
incompletely understood for parasympathetic neurons, as
research is often hampered by difficulties selectively injur-
ing these neurons, which are often found in close proxim-
ity or within their target organs [3]. Glial cell line-derived
neurotrophic factors, including glial cell line-derived neu-
rotrophic factor (GDNF), neurturin (NTN), persephin,
and artemin represent a class of novel agents with neuro-
protective and neuroregenerative properties [7]. The retro-
grade axonal transport mechanism of motor neurons has
previously been exploited to deliver the gene encoding
GDNF into the central nervous system, providing trophic
support following injury [8]. NTN and GDNF have also
been shown to promote survival and maintainence of cra-
nial parasympathetic neurons via a Ret receptor tyrosine-
kinase signalling component and a glycosylphosphati-
dylinositol-anchored GDNF family receptor α (GFRα)
protein receptor complex [9]. In vitro studies of neurturin
have demonstrated stimulation of parasympathetic neur-
ite extension from sacral ganglia tissue cultures via the
PI3-kinase pathway and suggest NTN acts as a target-
derived survival and/or neuritogenic factor for penile erec-
tion-inducing postganglionic neurons via a neurotrophic
signaling mechanism distinct from other parasympathetic
neurons [10-12]. To date, functional improvements sec-
ondary to neurturin treatment have not been tested. In
this study, the in vivo neuromodulatory effects of neur-
turin upon the recovery of erectile function following
bilateral cavernous nerve crush injury are demonstrated
using a rat model of neurogenic impotence.
Methods
Purification of neurturin
Recombinant rat neurturin (NTN) was expressed in E. coli
as an inclusion body. Cell lysis was performed on a micro-
fluidizer, repeated, and inclusion bodies were solubilized
in 6 M guanidine-HCL, 0.1 M sodium sulfite, 0.01 M
sodium terathionate and 0.02 M Tris pH 8.0 for 4 hours at
25°C. Separation of solubilized inclusion body rat NTN
was achieved by centrifugation at 7,000 rpm for 1 hour,
which was dialyzed in 4 M guanidine-HCL, 1 mM imida-
zole, and 0.01 M phosphate (pH 7.2). Unfolded rat NTN
was then purified on an affinity nickle charge resin Ni-
NTA superflow column (Qiagen Inc, Valencia, California,
USA). Solubilized rat NTN was washed with 10× (ten
times) column volume of 10 mM imidazole, and eluted
with 0.4 M imidazole. Rat NTN fractions were exchanged
in pre-refolding buffer containing 4 M urea, 0.1 M phos-
phate, 10% glycerol, 0.02 M glycine, and 0.02 M Tris pH
8.2. The refolding reaction was carried out by diluting rat
NTN 10× in 3 M urea, 15% glycerol, 0.075 M phosphate,
0.3 M NaCL, 0.02 M glycine, 2 mM cysteine, and 0.02 M
Tris pH 8.2, which was left incubating at 4°C for 48 hours.
Di-filtration was performed and refolded rat NTN was for-
mulated in 0.2 M sodium acetate pH 3.8. Refolded rat
NTN was further purified on Toyopearl 650 M-phenyl
sepharose HIC media (Tosoh Corp, Tokyo, Japan). Rat
NTN was then loaded in 0.2 M sodium acetate and 0.750
M NaCL. A 10× column volume wash was performed in 1
M NaCL, followed by elution of rat NTN in HIC media
with 0.2 M sodium acetate. Stripping of unfolded rat NTN
and contamination was achieved by adding 25% ETOH to
the HIC media. Finally, refolded rat NTN was formulated
into 10 mM sodium acetate pH 3.8.
Functional studies
Thirty-two male Sprague-Dawley rats (3 months old,
250–350 g) were randomly divided into four groups, each
containing eight animals. Control animals received a
sham operation only (identification of the cavernous
nerves bilaterally). The remaining 24 animals were
divided into 3 treatment cohorts (Groups A, B, and C).
Animals in the treatment groups underwent a bilateral
cavernous nerve crush injury, followed by direct injection
of either albumen (blinded control group), extended
release NT-4 or neurturin (dose of 100 ug per animal;
microspheres suspended in phosphate buffered solution)
to the site of injury. All animal experiments were
approved by the local ethical committee for experimenta-Journal of Brachial Plexus and Peripheral Nerve Injury 2007, 2:5 http://www.JBPPNI.com/content/2/1/5
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tion (University of California, San Francisco, Institutional
and Animal Care Use Committee) and complied with
National Institutes of Health (NIH) regulations for the
care and use of laboratory animals.
Animals were anesthetized for surgical procedures using
intraperitoneal ketamine (100 mg/kg) and xylazine (10
mg/kg) and kept isothermic on a heated pad. After the
animal was shaved, a lower midline abdominal incision
exposed the prostate gland and the cavernous nerves and
major pelvic ganglia (MPG) were identified bilaterally. No
additional pelvic surgical manipulation was performed in
the control group. In groups A, B, and C, the cavernous
nerves were carefully isolated and the crush injury
induced using a surgical needle driver at a constant 'one-
click' pressure for 2 minutes per side. The abdominal wall
was subsequently closed in two layers.
At 5 weeks, erectile function was assessed by measuring
maximal intracavernous pressure (ICP) upon direct cav-
ernous nerve electrostimulation. The cavernous nerves
were isolated via a repeat midline abdominal incision and
the crura of the penis was identified. A 23-gauge butterfly
needle with 250 U/ml heparin solution was inserted into
the penile crus and connected to polyethylene-50 tubing
for ICP measurement. A bipolar stainless steel hook elec-
trode (2 mm diameter probes separated by 1 mm) stimu-
lated the cavernous nerves. Monophasic rectangular
pulses were generated by a computer with a custom-built
constant current amplifier. The stimulus parameters were
1.5 mA, 20 Hz, pulse width 0.2 ms, and duration 50 s.
Each cavernous nerve was stimulated separately, ICP
measured using LabVIEW 4.0 software (National Instru-
ments, Austin, Texas), and mean maximal right and left
ICPs determined for each rat. Systemic blood pressure was
measured prior to terminating the procedure using a but-
terfly needle inserted into the aorta.
The data were first analyzed by non-repeated measures
ANOVA with significance considered at p < 0.05. If the dif-
ference was significant, Student Newman-Keuls test was
performed. All results were expressed as the mean ± SEM.
Animal weights prior to and following treatment were
compared. If an adverse event occurred, the cause of mor-
tality or early cessation of therapy (eg. weight loss, visible
lesions/tumor) and timepoint was noted. Investigators
were unblinded after statistical analyses were completed.
Results
To evaluate recovery of erectile function, the increase in
maximal intracavernous pressure (which correlates to
penile rigidity in men) was measured (Figure 1). Erectile
dysfunction was not observed in the uninjured control
group, which served to establish a baseline normal erectile
response to stimulation. The mean maximal intracavern-
ous pressure [ICP] increase observed was 117.5 ± 7.3
cmH2O. The blinded control group, which was treated
with albumin only, demonstrated a significant reduction
for increased ICP of 40.0 ± 6.3 cmH2O, consistent with a
state of erectile dysfunction. Neurturin facilitated the pres-
ervation of erectile function, with a mean ICP increase of
55%. The increase of 62.0 ± 9.2 cmH2O was statistically
significant (p < 0.05 vs control). Extended release neuro-
trophin-4 did not significantly enhance recovery of erec-
tile function with ICP changes of 46.9 ± 9.6 (Table 1). No
statistically significant differences were observed between
all groups for peak aortic blood pressure or weight gain.
There were no animal deaths or incomplete treatments in
this study.
Discussion
A clear clinical need for the development of therapeutic
neuromodulatory interventions has been defined as both
sympathetic and parasympathetic pelvic innervation is at
high risk of injury during surgery or radiation therapy for
prostate, bladder, and colorectal malignancies. Penile
erection, controlled by adrenergic, cholinergic, and non-
adrenergic noncholinergic (NANC) neuroeffectors carried
in the cavernous nerves, is often compromised by these
treatments, and subsequent patient quality-of-life dimin-
ished [4]. Despite advances in operative technique, the
probability of a man undergoing open radical retropubic
prostatectomy for clinically localized disease and achiev-
ing cancer-control, continence and potency is approxi-
mately 60% at 24 months [12]. Neurturin, which is
expressed in peripheral neuronal targets including the
penis, has demonstrated key neuromodulatory properties
including retrograde transport from the periphery to cell
Table 1: Intracavernous pressure increase in response to electrostimulation five weeks following bilateral cavernous nerve crush 
injury.
Group Cavernous Pressure Increase (mean cm H2O ± SEM)
a. Sham (uninjured) 117.5 ± 7.3
b. Albumin (blinded crush control) 40.0 ± 6.3###
c. Neurturin (100 ug) 62.0 ± 9.2**
d. Extended-release NT-4 (100 ug) 46.9 ± 9.6
###Versus Sham p < 0.001
**Versus Control p < 0.05Journal of Brachial Plexus and Peripheral Nerve Injury 2007, 2:5 http://www.JBPPNI.com/content/2/1/5
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body, enhancement of neuronal survival and promotion
of neurite outgrowth [13-15]. In this study, we demon-
strate neurturin's ability to confer an in vivo advantage for
the functional recovery of erectile function following cav-
ernous nerve injury.
Various methods of inducing injury to the cavernous
nerves are described in literature and include nerve
transection, cryoablation, crush and partial excision [16].
We prefer to use a controlled bilateral nerve crush tech-
nique, as significant but reversible damage to penile
innervation occurs and allows for the evaluation of func-
tional recovery. Advantages of this technique include sim-
plicity, reliability, and reproducibility, albeit the
relationship to surgical trauma incurred by prostatectomy
is inexact as the prostate itself is not removed [17].
Because NOS-containing nerves and neurons are the prin-
cipal sites where the erection-inducing neurotransmitter
nitric oxide (NO) is synthesized, their loss after nerve
injury is therefore chiefly responsible for the development
of ED. Using this animal model of neurogenic ED, we
have previously demonstrated a significant loss of nitric
oxide syntheses (NOS)-containing nerve fibers and neu-
rons in the corpora cavernosa and in the major pelvic gan-
glia (MPG) respectively, within one month of bilateral
cavernous nerve crush injury [18].
Neurturin applied directly to the area of injury facilitated
the preservation of erectile function as compared to
untreated control animals and extended release neuro-
trophin-4. The primary outcome measure, mean intracav-
ernous pressure increase, has been used extensively as the
measure of penile rigidity (function) in a wide variety of
ED animal models, and is a unifying factor for defining
Examples of intracavernous pressure changes after electrostimulation of the cavernous nerves at 5 weeks Figure 1
Examples of intracavernous pressure changes after electrostimulation of the cavernous nerves at 5 weeks. (a) Sham (uninjured) 
group, (b) albumin (crush control), (c) neurturin treatment, and (d) neurotrophin-4. The x-axis is in seconds, and the red line 
represents 50s of stimulation.
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response in the treatment of erectile dysfunction in
humans [19]. In a recently reported study investigating
the relationship between mean arterial pressure and ICP,
MacKenzie et al demonstrated that changes in ICP values
were adversely effected only when mean arterial pressure
(MAP) fell below 70 mmHg (regardless of the cause) [20].
Aortic pressures following determination of ICP did not
differ between groups and each animal demonstrated val-
ues of 100 mmHg or greater. Therefore, a carotid artery
catheter was not placed to monitor arterial pressure con-
currently with cavernous nerve stimulation as performed
in the past, minimizing undue operative morbidity and
physiologic stress on the rat as recommended by our Insti-
tutional Review Board. In addition, our preference is to
observe the wave form and the ICP change rather than the
ratio of ICP/BP; hypertensive patients can have abnormal
ICP/MAP ratios but sufficient penile rigidity (with intrac-
avernous pressures exceeding 100 mmHg) and would not
be labelled as impotent.
Following injury, compensatory and regenerative sprout-
ing of penile-projecting nerve fibres is likely driven by,
and dependent upon, various neurotrophic factors
including NTN, which is synthesized in urogenital tissues
including the penis and may also be secreted by glial cells
within the ganglion or glia associated with the injured
axon(s) [3]. Known receptors for neurturin include the
GDNF family receptors α1, α2 (predominant), and α4,
and have been identified in the major pelvic ganglion
[21]. Pelvic parasympathetic ganglion neurons respond to
axotomy by altering expression of NTN receptors; altered
glial secretions or glial coupling represent a complimen-
tary second mechanism of adapative signalling in early
phases of regeneration [3]. As penis-projecting pelvic neu-
rons express neuronal nitric oxide (nNOS) and GFRα2,
accumulating tissue culture, cell-line, in vivo signalling,
and with this report functional evidence, suggests that
neurturin plays a role in regeneration, as well as main-
tainence of adult parasympathetic neurons [11,22]. Given
the limitations of this pilot study, including unknown
optimal dosing or site of NTN delivery (crush site versus
major pelvic ganglion or penis), and an incomplete
understanding of the neurobiology of cavernous nerve
and neurturin interaction, results are encouraging and
warrant further study of NTN in this role. Following a sim-
ilar course to our investigations of brain-derived nerve
growth factor and its role in cavernous nerve response to
injury, we plan to focus upon identifying the primary
molecular signalling pathway(s), concentration-depend-
ent effects, and pattern(s) of endogenous neurturin
release in an effect to better delineate its neuroregenera-
tive or neuroprotective properties [23,24].
A growing body of literature suggests neurturin may rep-
resent a promising therapeutic agent for both central and
peripheral neurologic diseases states, enhancing survival,
differentiation, and regeneration of neurons alone or syn-
ergistically with other molecules. In addition to traumatic
injury, neurogenic impotence is often associated with dis-
eases related to sensory and/or peripheral neuropathy
such as diabetes mellitus [1]. As penile tissues are known
to express mRNA transcripts for at least 10 neurotrophic
factors, treatment strategies utilizing neurturin and these
neuromodulators alone or in combination may represent
future approaches to alleviate ED caused by injury, neuro-
logical or vascular changes [25,26]. From a broader per-
spective, elucidating the mechanisms by which neurturin
enhances peripheral nerve repair and functional recovery
may translate into clinical applications for such diverse
conditions as recurrent laryngeal nerve and brachial
plexus injuries, iatrogenic neuropraxias, or urinary incon-
tinence secondary to hysterectomy.
Conclusion
Treatment with neurturin at the site of cavernous nerve
crush injury facilitates recovery of erectile function in a
bilateral cavernous nerve crush injury model of erectile
dysfunction in the rat. Results support further investiga-
tion of neurturin as a neuroprotective and/or neuroregen-
erative agent following cavernous or other pelvic
autonomic nerve injuries.
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